Related references
Note: Only part of the references are listed.Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
Andrea Eisen et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Impact of MAF selection of patients for adjuvant bisphosphonate therapy and comparison with current clinical guidance
R. E. Coleman et al.
ANNALS OF ONCOLOGY (2022)
Code of practice needed for samples donated by trial participants
Robert Coleman et al.
LANCET ONCOLOGY (2022)
Ecology and evolution of dormant metastasis
Maria Teresa Blasco et al.
TRENDS IN CANCER (2022)
BONEMETASTASIS: MECHANISMS, THERAPIES, AND BIOMARKERS
Philippe Clezardin et al.
PHYSIOLOGICAL REVIEWS (2021)
Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer
Robert Coleman et al.
ADVANCES IN THERAPY (2021)
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment A Phase 3 Randomized Clinical Trial
Thomas W. P. Friedl et al.
JAMA ONCOLOGY (2021)
MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice
Alexander H. G. Paterson et al.
JNCI CANCER SPECTRUM (2021)
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307
Julie R. Gralow et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
Robert Coleman et al.
LANCET ONCOLOGY (2020)
Bone health in cancer: ESMO Clinical Practice Guidelines
R. Coleman et al.
ANNALS OF ONCOLOGY (2020)
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
Solange Peters et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Bone metastases
Robert E. Coleman et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Gnant et al.
LANCET ONCOLOGY (2019)
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
R. E. Coleman et al.
JOURNAL OF BONE ONCOLOGY (2018)
Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial
Robert Coleman et al.
LANCET ONCOLOGY (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer - An AZURE (BIG 01/04) sub-study
Caroline Wilson et al.
JOURNAL OF BONE ONCOLOGY (2017)
Characteristics and Significance of the Pre-metastatic Niche
Yang Liu et al.
CANCER CELL (2016)
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
Claire L. Vale et al.
LANCET ONCOLOGY (2016)
Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)
Manfred Wirth et al.
EUROPEAN UROLOGY (2015)
Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
Milica Pavlovic et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant et al.
LANCET (2015)
Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
Milica Pavlovic et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
Robert Coleman et al.
LANCET ONCOLOGY (2014)
Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis
Mari I. Suominen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study
G. V. Scagliotti et al.
ANNALS OF ONCOLOGY (2012)
Effects of Bone-Targeted Agents on Cancer Progression and Mortality
Robert Coleman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
Matthew R. Smith et al.
LANCET (2012)
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
Alexander H. G. Paterson et al.
LANCET ONCOLOGY (2012)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
Michael Gnant et al.
LANCET ONCOLOGY (2011)
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
Robert E. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] (vol 8, pg R13, 2006)
Trevor Powles et al.
BREAST CANCER RESEARCH (2006)
Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial
T Saarto et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
